Kiniksa Pharmaceuticals International (KNSA) EBT Margin (2021 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly EBT Margin came in at 12.79% in Q2 2026, down 180.0% on a YoY basis from 15.98% in Q2 2025, and down 16.18% quarter-over-quarter from 15.25% in Q1 2026.
Powered by 
Analysis
Kiniksa Pharmaceuticals International (KNSA) EBT Margin (2021 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has reported EBT Margin for 6 consecutive years, with 12.79% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT Margin fell 180.0% year-over-year to 12.79%; the trailing twelve-month figure through Jun 2026 stood at 13.59% (up 1089.0% YoY), and the FY2025 full-year result was 13.12%, up 2166.0% from the prior year.
- EBT Margin eased to 12.79% in Q2 2026 per KNSA's latest filing, from 15.25% in the prior quarter.
- Across five years, EBT Margin topped out at 146.9% in Q4 2022 and bottomed at 86.37% in Q4 2023.
- Historically, EBT Margin has averaged 1.41% across 5 years, with a median of 0.19% in 2024.
- The sharpest annual moves came in 2022 and 2023: EBT Margin jumped 45491 bps in 2022, then plunged 23327 bps in 2023.
- Over 5 years, EBT Margin stood at 146.9% in 2022, then tumbled by 159 bps to 86.37% in 2023, then soared by 84 bps to 13.86% in 2024, then surged by 183 bps to 11.51% in 2025, then rose by 11 bps to 12.79% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 12.79%, 15.25%, and 11.51% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -20,427.46% |
| 10 | Kiniksa Pharmaceuticals International | 6.09 Bn | 5.56 Bn | 220.03 Mn | 12.79% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.79% |
| Mar 31, 2026 | 15.25% |
| Dec 31, 2025 | 11.51% |
| Sep 30, 2025 | 15.02% |
| Jun 30, 2025 | 14.59% |
| Mar 31, 2025 | 11.30% |
| Dec 31, 2024 | -13.86% |
| Sep 30, 2024 | -6.42% |
| Jun 30, 2024 | 2.12% |
| Mar 31, 2024 | -17.88% |
| Dec 31, 2023 | -86.37% |
| Sep 30, 2023 | -12.68% |
| Jun 30, 2023 | -1.73% |
| Mar 31, 2023 | -19.37% |
| Dec 31, 2022 | 146.90% |
| Sep 30, 2022 | 47.14% |
| Jun 30, 2022 | -71.43% |
| Mar 31, 2022 | -72.34% |
| Dec 31, 2021 | -233.66% |
| Sep 30, 2021 | -253.51% |